Camila Valle

Dr. Camila Valle


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
CMCarolina Moraes
Carolina Moraes
CVCamila Valle
Camila Valle
RFRenaud Fleurance
Renaud Fleurance
TSTarek Sharshar
Tarek Sharshar
FBFernando Bozza
Fernando Bozza
Joana D'AvilaJoana D'Avila
Joana D'Avila
Frequently underestimated, encephalopathy or delirium are common neurological manifestations associated with sepsis. Brain dysfunction occurs in up to 80% of cases and is directly associated with increased mortality and long-term neurocognitive consequences. Although the central nervous system (CNS) has been classically viewed as an immune-privileged system, neuroinflammation is emerging as a central mechanism of brain dysfunction in sepsis. Microglial cells are major players in this setting. Here, we aimed to discuss the current knowledge on how the brain is affected by peripheral immune activation in sepsis and the role of microglia in these processes. This review focused on the molecular pathways of microglial activity in sepsis, its regulatory mechanisms, and their interaction with other CNS cells, especially with neuronal cells and circuits.

25 October 2022 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
CMCarolina Moraes
Carolina Moraes
EHEugenio DAMACENO Hottz
Eugenio DAMACENO Hottz
DODébora Dos Santos Ornellas
Débora Dos Santos Ornellas
DADaniel Adesse
Daniel Adesse
CACarolina T. de Azevedo
Carolina T. de Azevedo
FBFernando Bozza
Fernando Bozza

15 March 2016 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
FGFernanda Gubert
Fernanda Gubert
ADAna B. Decotelli
Ana B. Decotelli
IBIgor Bonacossa-Pereira
Igor Bonacossa-Pereira
FFFernanda R. Figueiredo
Fernanda R. Figueiredo
CVCamila Valle
Camila Valle
RMRosalia Mendez-Otero
Rosalia Mendez-Otero
Background: Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that selectively affects the motor neurons. The details of the mechanisms of selective motor-neuron death remain unknown and no effective therapy has been developed. We investigated the therapy with bone-marrow mononuclear cells (BMMC) in a mouse model of ALS (SOD1G93A mice). Methods: We injected 106 BMMC into the lumbar portion of the spinal cord of SOD1G93A mice in presymptomatic (9 weeks old) and symptomatic (14 weeks old) phases. In each condition, we analyzed the progression of disease and the lifespan of the animals. Results: We observed a mild transitory delay in the disease progression in the animals injected with BMMC in the presymptomatic phase. However, we observed no increase in the lifespan. When we injected BMMC in the symptomatic phase, we observed no difference in the animals’ lifespan or in the disease progression. Immunohistochemistry for NeuN showed a decrease in the number of motor neurons during the course of the disease, and this decrease was not affected by either treatment. Using different strategies to track the BMMC, we noted that few cells remained in the spinal cord after transplantation. This observation could explain why the BMMC therapy had only a transitory effect. Conclusion: This is the first report of intraspinal BMMC therapy in a mouse model of ALS. We conclude this cellular therapy has only a mild transitory effect when performed in the presymptomatic phase of the disease.

1 January 2017 in Stem Cells International
Verified
Journal Article
Open access
FGFernanda Gubert
Fernanda Gubert
CVCamila Valle
Camila Valle
MFMichelle Furtado
Michelle Furtado
PPPedro M. Pimentel-Coelho
Pedro M. Pimentel-Coelho
NMNicoli Mortari
Nicoli Mortari
MSMarcelo Felippe Santiago
Marcelo Felippe Santiago
CD60b antigens are highly expressed during development in the rat nervous system, while in the adult their expression is restricted to a few regions, including the subventricular zone (SVZ) around the lateral ventricles—a neurogenic niche in the adult brain. For this reason, we investigated whether the expression of C60b is associated with neural stem/progenitor cells in the SVZ, from development into adulthood. We performedin vitroandin vivoanalyses of CD60b expression at different stages and identified the presence of these antigens in neural stem/progenitor cells. We also observed that CD60b could be used to purify and enrich a population of neurosphere-forming cells from the developing and adult brain. We showed that CD60b antigens (mainly corresponding to ganglioside 9-O-acetyl GD3, a well-known molecule expressed during central nervous system development and mainly associated with neuronal migration) are also present in less mature cells and could be used to identify and isolate neural stem/progenitor cells during development and in the adult brain. A better understanding of molecules associated with neurogenesis may contribute not only to improve the knowledge about the physiology of the mammalian central nervous system, but also to find new treatments for regenerating tissue after disease or brain injury.

15 September 2023
Verified
Book Chapter
Closed access
MAMariana Alves Antunes
Mariana Alves Antunes
LBLeandra Santos Baptista
Leandra Santos Baptista
LBLuciano Figueiredo Borges
Luciano Figueiredo Borges
GCGiordano Wosgrau Calloni
Giordano Wosgrau Calloni
ACArnold I. Caplan
Arnold I. Caplan
CVCamila Valle
Camila Valle

15 September 2023
Verified
Book Chapter
Closed access
CVCamila Valle
Camila Valle
FGFernanda Gubert
Fernanda Gubert
JVJuliana Vasques
Juliana Vasques
LMLouise Alessandra Mesentier-Louro
Louise Alessandra Mesentier-Louro
ESEliana Scemes
Eliana Scemes
RMRosalia Mendez-Otero
Rosalia Mendez-Otero